The deafening public outcry over drug pricing has forced health insurers and pharmaceutical companies to devise ways of expanding access to potentially life-saving drugs without breaking the bank.
Value-based contracts, in which insurers pay for drugs based on their effectiveness, have begun to sprout, and more are expected to follow. But experts believe these types of deals, although potentially beneficial, are not a panacea for managing drug costs. Value-based contracts may also be hard to orchestrate since they require doctors, insurers, pharmacy benefit managers and drug companies, often rivals, to cooperate and share data.
Read Full Article »